Imamura Tetsuya, Ogawa Teruyuki, Minagawa Tomonori, Nagai Takashi, Suzuki Toshiro, Saito Tetsuichi, Yokoyama Hitoshi, Nakazawa Masaki, Ishizuka Osamu
Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan.
Neurourol Urodyn. 2017 Apr;36(4):1026-1033. doi: 10.1002/nau.23061. Epub 2016 Jul 1.
This study determined if combined treatment with the muscarinic receptor (MR) antagonist solifenacin and the β -adrenergic receptor (AR) agonist mirabegron could inhibit detrusor overactivity induced by cold stress in spontaneously hypertensive rats (SHRs).
Thirty-two female 10-week-old SHRs were fed an 8% NaCl-supplemented diet for 4 weeks. Cystometric measurements of the unanesthetized, unrestricted rats were performed at room temperature (RT, 27 ± 2°C) for 20 min. The rats were then intravenously administered vehicle, 0.1 mg/kg solifenacin alone, 0.1 mg/kg mirabegron alone, or the combination of 0.1 mg/kg mirabegron and 0.1 mg/kg solifenacin (n = 8 each group). Five minutes later, the treated rats were exposed to low temperature (LT, 4 ± 2°C) for 40 min. Finally, the rats were returned to RT. After the cystometric investigations, the β -ARs and M -MRs expressed within the urinary bladders were analyzed.
Just after transfer from RT to LT, vehicle-, solifenacin-, and mirabegron-treated SHRs exhibited detrusor overactivity that significantly decreased voiding interval and bladder capacity. However, treatment with the combination of solifenacin and mirabegron partially inhibited the cold stress-induced detrusor overactivity patterns. The decreases of voiding interval and bladder capacity in the combination-treated rats were significantly inhibited compared to other groups. Within the urinary bladders, there were no differences between expression levels of M -MR and β -AR mRNA. The tissue distribution of M -MRs was similar to that of the β -ARs.
This study suggested that the combination of solifenacin and mirabegron act synergistically to inhibit the cold stress-induced detrusor overactivity in SHRs. Neurourol. Urodynam. 36:1026-1033, 2017. © 2016 The Authors. Neurourology and Urodynamics Published by Wiley Periodicals, Inc.
本研究旨在确定毒蕈碱受体(MR)拮抗剂索利那新与β-肾上腺素能受体(AR)激动剂米拉贝隆联合治疗是否能抑制自发性高血压大鼠(SHR)冷应激诱导的逼尿肌过度活动。
32只10周龄雌性SHR喂食含8%氯化钠的饮食4周。在室温(RT,27±2°C)下对未麻醉、不受限制的大鼠进行20分钟的膀胱测压测量。然后,大鼠静脉注射溶剂、单独0.1mg/kg索利那新、单独0.1mg/kg米拉贝隆或0.1mg/kg米拉贝隆与0.1mg/kg索利那新的组合(每组n = 8)。5分钟后,将处理后的大鼠暴露于低温(LT,4±2°C)40分钟。最后,将大鼠放回RT。膀胱测压研究后,分析膀胱内表达的β-ARs和M-MRs。
刚从RT转移到LT后,溶剂、索利那新和米拉贝隆处理的SHR表现出逼尿肌过度活动,显著缩短排尿间隔和膀胱容量。然而,索利那新和米拉贝隆联合治疗部分抑制了冷应激诱导的逼尿肌过度活动模式。与其他组相比,联合治疗大鼠的排尿间隔和膀胱容量的降低得到显著抑制。在膀胱内,M-MR和β-AR mRNA的表达水平没有差异。M-MRs的组织分布与β-ARs相似。
本研究表明,索利那新和米拉贝隆联合作用可协同抑制SHR冷应激诱导的逼尿肌过度活动。《神经泌尿学与尿动力学》36:1026 - 1033,2017。©2016作者。《神经泌尿学与尿动力学》由威利期刊公司出版。